Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZIVO Bioscience, Inc. (ZIVO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly reports and other documents filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with a Commission File Number of 000-30415, ZIVO uses these filings to report material events, describe its business and update investors on governance and financial matters.
For a research and development company like ZIVO, SEC filings are a key source of information on its biotech and agtech activities involving proprietary algal and bacterial strains, biologically active molecules and complexes, and related intellectual property. Filings can explain how the company characterizes its focus on human and animal health applications, outline risk factors and summarize relationships with collaborators and counterparties.
Current reports on Form 8-K, such as the filing describing the resignation of a Chief Financial Officer and the appointment of an Interim Chief Financial Officer under an independent contractor services agreement, document significant management changes and associated compensation arrangements. Investors can also use this page to monitor future 10-K annual reports and 10-Q quarterly reports for updates on ZIVO’s R&D programs, liquidity, and any disclosed licensing or collaboration agreements.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in plain language, helping readers quickly understand lengthy documents. Real-time updates from EDGAR ensure that new ZIVO filings appear promptly, while access to ownership and insider transaction reports, such as Form 4 when filed, allows users to track equity-related activity by directors and officers. This combination of raw filings and AI analysis offers a structured way to review ZIVO’s regulatory history and ongoing disclosure record.
Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.
Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.
Zivo Bioscience director and 10% owner–associated entity acquires additional shares. On January 14, 2026, an entity associated with Laith L. Yaldoo, HEP Investments LLC, purchased 1,766 shares of Zivo Bioscience common stock at $8.49 per share in an open-market transaction.
Following this purchase, HEP Investments LLC indirectly holds 579,638 shares of Zivo Bioscience common stock attributed to Yaldoo’s beneficial ownership.
Zivo Bioscience, Inc. reported insider information for its Chief Financial Officer, William A. Sullivan, in a Form 3 initial ownership filing. The filing shows that as of the event date of 12/19/2025, he reported beneficial ownership of 0 shares of Zivo Bioscience, Inc. common stock and no derivative securities such as options or warrants. The form is filed as an individual reporting person and confirms that he currently holds no direct or indirect equity or derivative position in the company.
Zivo Bioscience, Inc. reported that Chief Financial Officer Keith R. Marchiando has resigned from his CFO role effective immediately and will end his employment on December 31, 2025. Under a separation and release agreement, he will continue to receive his current salary of $27,040 per month through December 31, 2026, and will retain an option to acquire 150,000 shares of common stock at an exercise price of $7.96 per share, exercisable until June 30, 2027.
The company appointed William A. Sullivan as Interim Chief Financial Officer effective December 19, 2026, under an independent contractor services agreement. He will be paid $285.00 per hour for his work, with an initial 60-day term that automatically renews for one-month periods unless either party provides notice. Mr. Sullivan is subject to confidentiality and post-termination restrictions aimed at protecting the company’s business relationships.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.
ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.
Zivo Bioscience (ZIVO): Insider transaction reported. Affiliates of Strome Group reported a purchase of Zivo Bioscience common stock and warrants on 10/13/2025. The filing shows a purchase of 20,259 shares of common stock at $12.34 per share, held indirectly by an entity.
The report also lists acquisition of 2,025 Common Stock Purchase Warrants with an exercise price of $12.34, exercisable on 10/13/2025 and expiring on 10/12/2030. Following these transactions, the filing shows 452,942 common shares and 43,071 derivative securities beneficially owned indirectly by the reporting entity. The securities were acquired pursuant to a Securities Purchase Agreement.
Zivo Bioscience (ZIVO) reported an insider purchase. Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock on 10/10/2025 at $12.05 per share, held indirectly through HEP Investments LLC. Following the trade, beneficial ownership was 575,095 shares, reported as indirect.
Christopher D. Maggiore, a director and reported >10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 23,682 shares of the companys common stock on 10/08/2025 at a price of $12.01 per share. After this transaction the filing reports aggregate beneficial ownership of 517,526 shares, which corrects a prior overstatement caused by an administrative error that had overstated ownership by 13,156 shares. The transaction is reported on a Form 4 and was signed by the reporting person on 10/09/2025. The filing shows the acquisition coded as P and lists the ownership form as Direct.
Zivo Bioscience (ZIVO) reported an insider equity award. On 10/02/2025, a reporting person who is a Director and 10% Owner received 926 nonstatutory stock options to buy common stock at an exercise price of $12.03 per share, expiring on 10/02/2035. The filing notes the option grant was issued under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $9,452.05. Ownership of these derivative securities is listed as Direct (D).